Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tetratricopeptide repeat protein 19, mitochondrial (TTC19)
- Target
- TTC19
- Molecular classification
- Enzyme subunit (complex III assembly factor), Tetratricopeptide repeat domain protein, Other (not a receptor, transporter, ion channel, or transcription factor)
01
Overview
Tetratricopeptide repeat protein 19, mitochondrial (TTC19) is encoded by the TTC19 gene on chromosome 17p12. Its protein product is a mitochondrial inner membrane protein composed of several tetratricopeptide repeat domains, mediating protein-protein interactions. TTC19 is required for structural and functional integrity of mitochondrial complex III, facilitating turnover of the Rieske protein UQCRFS1 and clearing detrimental protein fragments during complex assembly, essential for respiratory electron transport and ATP generation. Mutations in TTC19 cause mitochondrial complex III deficiency, manifesting as neuromuscular, neurological, and multi-organ symptoms with autosomal recessive inheritance. TTC19 deficiency leads to failed complex III assembly and impaired cellular energy metabolism, contributing to mitochondrial disease syndromes[1][2][3][5].
- Other names
- TTC19TPR repeat protein 19Tetratricopeptide repeat domain 19FLJ20343MGC195202010204O13RikMC3DN2
02
Biological functions
Mitochondrial respiratory chain complex III assembly and integrityClearance of N-terminal fragments of the Rieske protein UQCRFS1, preserving complex III catalytic activityATP synthesis via electron transport chainPossibly involved in cytokinesis
03
Disease associations
Mitochondrial complex III deficiency (nuclear type 2, MC3DN2; autosomal recessive)Mitochondrial encephalopathyProgressive movement disorders and peripheral neuropathyNeurological impairment (ataxia, psychomotor retardation, cognitive dysfunction)Severe failure to thrive, liver/renal dysfunction, muscle weakness, exercise intolerance (in context of deficiency)
04
Safety considerations
Loss-of-function mutations can cause severe mitochondrial dysfunction and multisystemic diseasesNot relevant for drug safety, as TTC19 is not a direct pharmacological target
05
Biomarkers
TTC19 gene mutation is a biomarker for mitochondrial complex III deficiencyMay aid diagnosis in patients with relevant clinical phenotypes (neuromuscular and neurological symptoms)
Beyond the preview
Go deeper on Tetratricopeptide repeat protein 19, mitochondrial (TTC19).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tetratricopeptide repeat protein 19, mitochondrial (TTC19).